amantadine has been researched along with Sensitivity and Specificity in 19 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability." | 2.78 | Which dyskinesia scale best detects treatment response? ( Chung, KA; Ge, S; Goetz, CG; Hauser, RA; Jaglin, JA; Miyasaki, JM; Nicholas, AP; Nutt, JG; Poewe, W; Rascol, O; Seppi, K; Stacy, MA; Stebbins, GT; Tanner, CM; Urkowitz, A, 2013) |
| "We report a case of human rabies diagnosed by the metagenomics next-generation sequencing (mNGS)." | 1.72 | A new choice for human rabies diagnosis: A case report of metagenomics next-generation sequencing in diagnosis of human rabies. ( Linjie, L; Lutao, X; Pin, L; Qunjie, P; Wang, D; Weijun, F, 2022) |
| "Resistance of influenza viruses to antiviral drugs can emerge following medication or may result from natural variation." | 1.35 | Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. ( Balish, A; Bright, RA; Deyde, VM; Gubareva, LV; Klimov, AI; Lindstrom, S; Nguyen, T; Shu, B, 2009) |
| " Only amantadine preparations are available on our local market, and application of the method to the analysis of amantadine in formulation and in the urine of a dosed subject was demonstrated and proved feasible." | 1.33 | Fluorimetric liquid chromatographic analysis of amantadine in urine and pharmaceutical formulation. ( Duh, TH; Kou, HS; Pan, CW; Wu, HL, 2005) |
| "To determine the cost-effectiveness of influenza testing and treatment strategies for older adults." | 1.32 | Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. ( Bellantonio, S; Rose, DN; Rothberg, MB, 2003) |
| "Amantadine was used as an internal standard." | 1.31 | Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. ( Fauler, G; Leis, HJ; Windischhofer, W, 2002) |
| "Amantadine was extracted from plasma into toluene under alkaline conditions and the residue was derivatized with the far-red label Cy5." | 1.30 | Visible diode laser induced fluorescence detection for capillary electrophoretic analysis of amantadine in human plasma following precolumn derivatization with Cy5.29.OSu. ( Karnes, HT; Nagaraj, S; Rahavendran, SV, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Pin, L | 1 |
| Lutao, X | 1 |
| Linjie, L | 1 |
| Qunjie, P | 1 |
| Weijun, F | 1 |
| Wang, D | 1 |
| Okhina, AA | 1 |
| Rogachev, AD | 1 |
| Yarovaya, OI | 1 |
| Khvostov, MV | 1 |
| Tolstikova, TG | 1 |
| Pokrovsky, AG | 1 |
| Khazanov, VA | 1 |
| Salakhutdinov, NF | 1 |
| Deyde, VM | 1 |
| Nguyen, T | 1 |
| Bright, RA | 1 |
| Balish, A | 1 |
| Shu, B | 1 |
| Lindstrom, S | 1 |
| Klimov, AI | 1 |
| Gubareva, LV | 1 |
| Suzuki, Y | 1 |
| Saito, R | 1 |
| Zaraket, H | 1 |
| Dapat, C | 1 |
| Caperig-Dapat, I | 1 |
| Suzuki, H | 1 |
| Yeh, HH | 1 |
| Yang, YH | 1 |
| Chen, SH | 1 |
| Wang, Z | 1 |
| Wang, X | 1 |
| He, Z | 1 |
| Liu, ZL | 1 |
| Wei, XL | 1 |
| Yin, X | 1 |
| Zhou, JM | 1 |
| Li, XY | 1 |
| Zhang, ZZ | 1 |
| Cen, S | 1 |
| Goetz, CG | 1 |
| Stebbins, GT | 1 |
| Chung, KA | 1 |
| Hauser, RA | 1 |
| Miyasaki, JM | 1 |
| Nicholas, AP | 1 |
| Poewe, W | 1 |
| Seppi, K | 1 |
| Rascol, O | 1 |
| Stacy, MA | 1 |
| Nutt, JG | 1 |
| Tanner, CM | 1 |
| Urkowitz, A | 1 |
| Jaglin, JA | 1 |
| Ge, S | 1 |
| Leis, HJ | 1 |
| Fauler, G | 1 |
| Windischhofer, W | 1 |
| Zhang, J | 1 |
| Zhang, XS | 1 |
| Rothberg, MB | 1 |
| Bellantonio, S | 1 |
| Rose, DN | 1 |
| Duh, TH | 1 |
| Wu, HL | 1 |
| Pan, CW | 1 |
| Kou, HS | 1 |
| Shuangjin, C | 1 |
| Fang, F | 1 |
| Han, L | 1 |
| Ming, M | 1 |
| Rakestraw, D | 1 |
| Prud'homme, IT | 1 |
| Zoueva, O | 1 |
| Weber, JM | 1 |
| Nieuwboer, A | 1 |
| De Weerdt, W | 1 |
| Dom, R | 1 |
| Lesaffre, E | 1 |
| Nagaraj, S | 1 |
| Rahavendran, SV | 1 |
| Karnes, HT | 1 |
| Yoshida, H | 1 |
| Nakao, R | 1 |
| Matsuo, T | 1 |
| Nohta, H | 1 |
| Yamaguchi, M | 1 |
| Masek, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
1 review available for amantadine and Sensitivity and Specificity
| Article | Year |
|---|---|
Current status and problems in preclinical assessment of immunomodulators.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Amantadine; Animals; Dipeptides; DNA Repl | 1992 |
1 trial available for amantadine and Sensitivity and Specificity
| Article | Year |
|---|---|
Which dyskinesia scale best detects treatment response?
Topics: Aged; Amantadine; Analysis of Variance; Antiparkinson Agents; Dose-Response Relationship, Drug; Doub | 2013 |
17 other studies available for amantadine and Sensitivity and Specificity
| Article | Year |
|---|---|
A new choice for human rabies diagnosis: A case report of metagenomics next-generation sequencing in diagnosis of human rabies.
Topics: Amantadine; Animals; Dogs; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Pulmona | 2022 |
Development and validation of an LC-MS/MS method for the quantitative analysis of the anti-influenza agent camphecene in rat plasma and its application to study the blood-to-plasma distribution of the agent.
Topics: Amantadine; Animals; Biosensing Techniques; Blood Specimen Collection; Calibration; Camphor; Chromat | 2020 |
Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.
Topics: Amantadine; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Genetic Markers; Humans; Influ | 2009 |
Rapid and specific detection of amantadine-resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method.
Topics: Amantadine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A V | 2010 |
Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
Topics: Acetonitriles; Alzheimer Disease; Amantadine; Antiparkinson Agents; Chemical Fractionation; Chromato | 2010 |
[Establishment of drug screening assay and pharmacodynamic evaluation method targeting influenza RNA polymerase].
Topics: Alphainfluenzavirus; Amantadine; Antiviral Agents; Drug Evaluation, Preclinical; Genes, Reporter; HE | 2012 |
Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry.
Topics: Amantadine; Antiparkinson Agents; Biological Availability; Blood Preservation; Calibration; Cryopres | 2002 |
[Assay for paracetamol by derivative spectrophotometry in compound amantadine tablets].
Topics: Acetaminophen; Amantadine; Antiviral Agents; Caffeine; Drug Combinations; Pharmaceutical Preparation | 2002 |
Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision | 2003 |
Summaries for patients. Cost-effective management of flu in adults older than 65 years of age.
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision | 2003 |
Fluorimetric liquid chromatographic analysis of amantadine in urine and pharmaceutical formulation.
Topics: Amantadine; Calibration; Chromatography, High Pressure Liquid; Humans; Pharmaceutical Preparations; | 2005 |
New method for high-performance liquid chromatographic determination of amantadine and its analogues in rat plasma.
Topics: Amantadine; Animals; Antiviral Agents; Calibration; Chromatography, High Pressure Liquid; Drug Stabi | 2007 |
Determination of amantadine in human plasma by capillary gas chromatography using electron-capture detection following derivatization with pentafluorobenzoyl chloride.
Topics: Administration, Oral; Adult; Amantadine; Benzoates; Chromatography, Gas; Humans; Hydrogen-Ion Concen | 1993 |
Amantadine susceptibility in influenza A virus isolates: determination methods and lack of resistance in a Canadian sample, 1991-94.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance; Enzyme-Linked Immunosorbent Assay; | 1997 |
A frequency and correlation analysis of motor deficits in Parkinson patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; | 1998 |
Visible diode laser induced fluorescence detection for capillary electrophoretic analysis of amantadine in human plasma following precolumn derivatization with Cy5.29.OSu.
Topics: Amantadine; Electrophoresis, Capillary; Fluorescence; Fluorescent Dyes; Humans; Hydrogen-Ion Concent | 1998 |
4-(6,7-Dihydro-5,8-dioxothiazolo[4,5-g]phthalazin-2-yl)benzoic acid N-hydroxysuccinimide ester as a highly sensitive chemiluminescence derivatization reagent for amines in liquid chromatography.
Topics: Adult; Amantadine; Amines; Calibration; Humans; Indicators and Reagents; Luminescent Measurements; M | 2001 |